Xenon ( (XENE) ) has issued an update.
Xenon Pharmaceuticals announced its participation in the Stifel 2025 Virtual CNS Forum, where Dr. Chris Kenney, the Chief Medical Officer, will present. This event highlights Xenon’s commitment to engaging with stakeholders and showcasing its advancements in neuroscience therapeutics, potentially strengthening its position in the biopharmaceutical industry.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. The company is advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Its most advanced product, Azetukalner, is a novel, highly potent, selective Kv7 potassium channel opener in late-stage clinical development for multiple indications.
YTD Price Performance: -13.47%
Average Trading Volume: 455,839
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.66B
For a thorough assessment of XENE stock, go to TipRanks’ Stock Analysis page.